Tetracyclines and neuromuscular disorders

Current Neuropharmacology

Volumn 10, Issue 2, 2012, Pages 134-138

  Orsucci, Daniele ^a   Mancuso, Michelangelo ^a   Siciliano, Gabriele ^a   Filosto, Massimiliano ^b  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Doxycycline; Minocycline; Mitochondria; Neurodegeneration; PARP 1; Progressive external ophthalmoplegia; ROS; Tetracycline

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; DOXYCYCLINE; MINOCYCLINE; MITOCHONDRIAL DNA; PLACEBO; RILUZOLE; TETRACYCLINE; TETRACYCLINE DERIVATIVE;

AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; DIABETIC NEUROPATHY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFICACY; DRUG SAFETY; HUMAN; MITOCHONDRION; MOTOR DYSFUNCTION; MUSCULAR DYSTROPHY; NEUROMUSCULAR DISEASE; NEUROPATHIC PAIN; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; REVIEW; SURVIVAL;

EID: 84861747058     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/157015912800604498     Document Type: Review

References (45)

1. Orsucci, D.; Calsolaro, V.; Mancuso, M.; Siciliano, G. Neuroprotective effects of tetracyclines: molecular targets, animal models and human disease. CNS Neurol. Disord. Drug Targets, 2009, 8(3), 222-231.
2. Yong, V.W.; Wells, J.; Giuliani, F.; Casha, S.; Power, C.; Metz, L.M. The promise of minocycline in neurology. Lancet Neurol., 2004, 3(12), 744-751.
3. Lampl, Y.; Boaz, M.; Gilad, R.; Lorberboym, M.; Dabby, R.; Rapoport, A.; Anca-Hershkowitz, M.; Sadeh, M. Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology, 2007, 69(14), 1404-1410.
4. Metz, L.M.; Zhang, Y.; Yeung, M.; Patry, D.G.; Bell, R.B.; Stoian, C.A.; Yong, V.W.; Patten, S.B.; Duquette, P.; Antel, J.P.; Mitchell, J.R. Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann. Neurol., 2004, 55(5), 756.
5. Zabad, R.K.; Metz, L.M.; Todoruk, T.R.; Zhang, Y.; Mitchell, J.R.; Yeung, M.; Patry, D.G.; Bell, R.B.; Yong, V.W. The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study. Mult. Scler., 2007, 13(4), 517-526.
6. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology, 2006, 66(5), 664-671.
7. Bonelli, R.M.; Hodl, A.K.; Hofmann, P.; Kapfhammer, H.P. Neuroprotection in Huntington's disease: a 2-year study on minocycline. Int. Clin. Psychopharmacol., 2004, 19(6), 337-342.
8. Paribello, C.; Tao, L.; Folino, A.; Berry-Kravis, E.; Tranfaglia, M.; Ethell, I.M.; Ethell, D.W. Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurol., 2010, 10, 91.
9. Schildknecht, S.; Pape, R.; Muller, N.; Robotta, M.; Marquardt, A.; Burkle, A.; Drescher, M.; Leist, M. Neuroprotection by minocycline caused by direct and specific scavenging of peroxynitrite. J. Biol. Chem., 2011, 286(7), 4991-5002.
10. Tao, R.; Kim, S.H.; Honbo, N.; Karliner, J.S.; Alano, C.C. Minocycline protects cardiac myocytes against simulated ischemiareperfusion injury by inhibiting poly(ADP-ribose) polymerase-1. J. Cardiovasc. Pharmacol., 2010, 56(6), 659-668.
11. Zhu, S.; Stavrovskaya, I.G.; Drozda, M.; Kim, B.Y.; Ona, V.; Li, M.; Sarang, S.; Liu, A.S.; Hartley, D.M.; Wu, D.C.; Gullans, S.; Ferrante, R.J.; Przedborski, S.; Kristal, B.S.; Friedlander, R.M. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature, 2002, 417(6884), 74-78.
12. Shefer, G.; Carmeli, E.; Rauner, G.; Yablonka-Reuveni, Z.; Benayahu, D. Exercise running and tetracycline as means to enhance skeletal muscle stem cell performance after external fixation. J. Cell Physiol., 2008, 215(1), 265-275.
13. Crugnola, V.; Lamperti, C.; Lucchini, V.; Ronchi, D.; Peverelli, L.; Prelle, A.; Sciacco, M.; Bordoni, A.; Fassone, E.; Fortunato, F.; Corti, S.; Silani, V.; Bresolin, N.; Di Mauro, S.; Comi, G.P.; Moggio, M. Mitochondrial respiratory chain dysfunction in muscle from patients with amyotrophic lateral sclerosis. Arch. Neurol., 2010, 67(7), 849-854.
14. Mancuso, M.; Filosto, M.; Orsucci, D.; Siciliano, G. Mitochondrial DNA sequence variation and neurodegeneration. Hum. Genomics, 2008, 3(1), 71-78.
15. Tikka, T.M.; Vartiainen, N.E.; Goldsteins, G.; Oja, S.S.; Andersen, P.M.; Marklund, S.L.; Koistinaho, J. Minocycline prevents neurotoxicity induced by cerebrospinal fluid from patients with motor neurone disease. Brain, 2002, 125(Pt 4), 722-731.
16. Keller, A.F.; Gravel, M.; Kriz, J. Treatment with minocycline after disease onset alters astrocyte reactivity and increases microgliosis in SOD1 mutant mice. Exp. Neurol., 2011, 228(1), 69-79.
17. Milane, A.; Tortolano, L.; Fernandez, C.; Bensimon, G.; Meininger, V.; Farinotti, R. Brain and plasma riluzole pharmacokinetics: effect of minocycline combination. J. Pharm. Pharm. Sci., 2009, 12(2), 209-217.
18. Pontieri, F.E.; Ricci, A.; Pellicano, C.; Benincasa, D.; Buttarelli, F.R. Minocycline in amyotrophic lateral sclerosis: a pilot study. Neurol. Sci., 2005, 26(4), 285-287.
19. Gordon, P.H.; Moore, D.H.; Miller, R.G.; Florence, J.M.; Verheijde, J.L.; Doorish, C.; Hilton, J.F.; Spitalny, G.M.; MacArthur, R.B.; Mitsumoto, H.; Neville, H.E.; Boylan, K.; Mozaffar, T.; Belsh, J.M.; Ravits, J.; Bedlack, R.S.; Graves, M.C.; McCluskey, L.F.; Barohn, R.J.; Tandan, R. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol., 2007, 6(12), 1045-1053.
20. Zhang, Z.Y.; Zhang, Z.; Fauser, U.; Schluesener, H.J. Improved outcome of EAN, an animal model of GBS, through amelioration of peripheral and central inflammation by minocycline. J. Cell Mol. Med., 2009, 13(2), 341-351.
21. Yi, C.; Zhang, Z.; Wang, W.; Zug, C.; Schluesener, H.J. Doxycycline attenuates peripheral inflammation in rat experimental autoimmune neuritis. Neurochem. Res., 2011, 36(11), 1984-90.
22. Pabreja, K.; Dua, K.; Sharma, S.; Padi, S.S.; Kulkarni, S.K. Minocycline attenuates the development of diabetic neuropathic pain: possible anti-inflammatory and anti-oxidant mechanisms. Eur. J. Pharmacol., 2011, 661(1-3), 15-21.
23. Mei, X.P.; Xu, H.; Xie, C.; Ren, J.; Zhou, Y.; Zhang, H.; Xu, L.X. Post-injury administration of minocycline: an effective treatment for nerve-injury induced neuropathic pain. Neurosci. Res., 2011, 70(3), 305-312.
24. Chang, Y.W.; Waxman, S.G. Minocycline attenuates mechanical allodynia and central sensitization following peripheral seconddegree burn injury. J. Pain, 2010, 11(11), 1146-1154.
25. Boyette-Davis, J.; Dougherty, P.M. Protection against oxaliplatininduced mechanical hyperalgesia and intraepidermal nerve fiber loss by minocycline. Exp. Neurol., 2011, 229(2), 353-357.
26. Liu, C.C.; Lu, N.; Cui, Y.; Yang, T.; Zhao, Z.Q.; Xin, W.J.; Liu, X.G. Prevention of paclitaxel-induced allodynia by minocycline: Effect on loss of peripheral nerve fibers and infiltration of macrophages in rats. Mol. Pain, 2010, 6, 76.
27. Li, K.; Fu, K.Y.; Light, A.R.; Mao, J. Systemic minocycline differentially influences changes in spinal microglial markers following formalin-induced nociception. J. Neuroimmunol., 2010, 221(1-2), 25-31.
28. Kim, T.H.; Kim, H.I.; Kim, J.; Park, M.; Song, J.H. Effects of minocycline on Na(+) currents in rat dorsal root ganglion neurons. Brain Res., 2011, 1370, 34-42.
29. Nie, H.; Zhang, H.; Weng, H.R. Minocycline prevents impaired glial glutamate uptake in the spinal sensory synapses of neuropathic rats. Neuroscience, 2010, 170(3), 901-912.
30. Mika, J.; Rojewska, E.; Makuch, W.; Przewlocka, B. Minocycline reduces the injury-induced expression of prodynorphin and pronociceptin in the dorsal root ganglion in a rat model of neuropathic pain. Neuroscience, 2010, 165(4), 1420-1428.
31. Davies, J.E.; Wang, L.; Garcia-Oroz, L.; Cook, L.J.; Vacher, C.; O'Donovan, D.G.; Rubinsztein, D.C. Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice. Nat. Med., 2005, 11(6), 672-677.
32. Girgenrath, M.; Beermann, M.L.; Vishnudas, V.K.; Homma, S.; Miller, J.B. Pathology is alleviated by doxycycline in a lamininalpha2-null model of congenital muscular dystrophy. Ann. Neurol., 2009, 65(1), 47-56.
33. Homma, S.; Beermann, M.L.; Miller, J.B. Peripheral nerve pathology, including aberrant Schwann cell differentiation, is ameliorated by doxycycline in a laminin-alpha2-deficient mouse model of congenital muscular dystrophy. Hum. Mol. Genet., 2011, 20(13), 2662-2672.
34. DiMauro, S.; Schon, E.A. Mitochondrial respiratory-chain diseases. N. Engl. J. Med., 2003, 348(26), 2656-2668.
35. Schaefer, A.M.; McFarland, R.; Blakely, E.L.; He, L.; Whittaker, R.G.; Taylor, R.W.; Chinnery, P.F.; Turnbull, D.M. Prevalence of mitochondrial DNA disease in adults. Ann. Neurol., 2008, 63(1), 35-39.
36. Mancuso, M.; Orsucci, D.; Logerfo, A.; Rocchi, A.; Petrozzi, L.; Nesti, C.; Galetta, F.; Santoro, G.; Murri, L.; Siciliano, G. Oxidative stress biomarkers in mitochondrial myopathies, basally and after cysteine donor supplementation. J. Neurol., 2010, 257(5), 774-781.
37. Chinnery, P.; Majamaa, K.; Turnbull, D.; Thorburn, D. Treatment for mitochondrial disorders. Cochrane Database Syst. Rev., 2006(1), CD004426.
38. Haroon, M.F.; Fatima, A.; Scholer, S.; Gieseler, A.; Horn, T.F.; Kirches, E.; Wolf, G.; Kreutzmann, P. Minocycline, a possible neuroprotective agent in Leber's hereditary optic neuropathy (LHON): studies of cybrid cells bearing 11,778 mutation. Neurobiol. Dis., 2007, 28(3), 237-250.
39. Omar, A.; Johnson, L.N. Tetracycline delays ocular motility decline in chronic progressive external ophthalmoplegia. Neurology, 2007, 68(14), 1159-1160.
40. Mancuso, M.; Orsucci, D.; Calsolaro, V.; Logerfo, A.; Allegrini, L.; Petrozzi, L.; Simoncini, C.; Rocchi, A.; Trivella, F.; Murri, L.; Siciliano, G. Tetracycline treatment in patients with progressive external ophthalmoplegia. Acta Neurol. Scand., 2011, 124(6), 417-23.
41. Zoraster, R.M.; Rison, R.A. Severe lactic acidosis secondary to minocycline in a teenager with infectious mononucleosis and mitochondrial myopathy. Clin. Neurol. Neurosurg., 2008, 110(6), 627-630.
42. Kupsch, K.; Hertel, S.; Kreutzmann, P.; Wolf, G.; Wallesch, C.W.; Siemen, D.; Schonfeld, P. Impairment of mitochondrial function by minocycline. FEBS J., 2009, 276(6), 1729-1738.
43. Jones, C.N.; Miller, C.; Tenenbaum, A.; Spremulli, L.L.; Saada, A. Antibiotic effects on mitochondrial translation and in patients with mitochondrial translational defects. Mitochondrion, 2009, 9(6), 429-437.
44. Plane, J.M.; Shen, Y.; Pleasure, D.E.; Deng, W. Prospects for minocycline neuroprotection. Arch. Neurol., 2010, 67(12), 1442-1448.
45. Gu, Y.; Lee, H.M.; Simon, S.R.; Golub, L.M. Chemically modified tetracycline-3 (CMT-3): A novel inhibitor of the serine proteinase, elastase. Pharmacol. Res., 2011, 64(6), 595-601.